• Home
  •  / Nektar Therapeutics

Nektar Therapeutics

OverviewSuggest Edit

Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

TypePublic
Founded1990
HQSan Francisco, CA, USMap
Websitenektar.com
Employee Ratings3.3More
Overall CultureB-More
View Jobs (56)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)618(+22%)
Job Openings56
Revenue (FY, 2020)$152.9 M(+34%)
Share Price (May 2021)$19

Key People/Management at Nektar Therapeutics

Jeff Ajer

Jeff Ajer

Director
Robert B. Chess

Robert B. Chess

Chairman of the Board
Gil M. Labrucherie

Gil M. Labrucherie

Chief Operating Officer and Chief Financial Officer
R. Scott Greer

R. Scott Greer

Director
Myriam J. Curet

Myriam J. Curet

Director
Kevin Brodbeck

Kevin Brodbeck

Senior Vice President of Manufacturing
Show more

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, CA, US (HQ)
455 Mission Bay Boulevard South, San Francisco
Huntsville, AL, US
1112 Church St NW
Hyderabad, IN
Main Rd, Hashmath Gunj, Goutam Nagar, Badi Chowdi, Kachiguda
Show all (3)

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Revenue

Embed Graph
View revenue for all periods
Nektar Therapeutics's revenue was reported to be $152.92 m in FY, 2020
USD

Revenue (FY, 2020)

152.9m

Gross profit (FY, 2020)

133.4m

Gross profit margin (FY, 2020), %

87.3%

Net income (FY, 2020)

(444.4m)

EBIT (FY, 2020)

(425.1m)

Market capitalization (14-May-2021)

3.5b

Closing stock price (14-May-2021)

19.0

Cash (31-Dec-2020)

199.0m

EV

3.4b
Nektar Therapeutics's current market capitalization is $3.5 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

71.5m81.2m148.9m200.7m230.8m230.8m165.4m307.7m1.2b114.6m152.9m

Revenue growth, %

35%15%(28%)

Cost of goods sold

21.9m30.4m38.5m28.5m34.1m34.1m30.2m30.5m24.4m21.4m19.5m

Gross profit

49.6m50.8m110.4m172.2m196.7m196.7m135.2m277.2m1.2b93.2m133.4m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

11.3m17.3m27.1m17.9m23.7m18.4m23.0m33.9m60.9m19.8m28.5m132.9m108.8m22.7m60.0m58.9m32.8m36.3m24.7m34.6m152.9m38.0m1.1b27.8m28.2m23.3m29.2m50.6m5.5m5.7m

Cost of goods sold

3.3m8.1m5.0m8.7m7.2m7.2m11.7m5.0m12.9m7.9m5.1m9.2m8.4m10.5m6.8m8.9m7.7m7.0m6.1m9.0m5.7m6.6m5.4m5.0m4.9m3.8m

Gross profit

8.0m9.2m22.0m9.2m16.5m11.2m11.3m28.9m48.0m11.9m23.4m123.7m100.4m12.1m53.2m50.0m25.1m29.3m18.6m25.6m147.3m31.4m22.8m18.3m24.3m46.8m

Gross profit Margin, %

71%53%81%51%70%61%49%85%79%60%82%93%92%54%89%85%76%81%75%74%96%83%81%78%83%92%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

15.3m25.4m39.1m12.4m55.6m59.6m4.8m194.9m96.4m199.0m

Accounts Receivable

4.9m5.8m2.2m3.6m19.9m5.0m43.2m36.8m38.9m

Prepaid Expenses

17.9m13.4m5.2m8.8m9.8m14.9m21.3m15.4m

Inventories

12.7m18.3m13.5m13.0m11.3m11.1m10.7m11.4m12.7m15.3m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

22.5m11.6m43.0m148.5m136.2m10.3m28.5m41.4m65.4m32.4m30.7m32.0m129.5m20.9m18.8m72.5m55.7m63.3m23.5m16.1m38.0m34.8m911.1m222.3m106.8m85.4m81.2m227.0m58.2m55.8m

Accounts Receivable

2.2m8.5m12.9m10.8m11.4m3.9m3.6m6.0m4.6m1.9m3.0m46.1m2.9m3.7m3.0m39.7m27.8m14.2m1.6m4.1m3.3m15.6m35.3m31.9m42.9m37.3m41.2m42.0m47.2m42.9m

Prepaid Expenses

6.9m7.9m7.6m13.6m9.3m7.0m8.8m6.0m4.8m6.0m4.6m4.7m6.1m8.8m5.2m5.6m5.4m4.0m7.9m7.5m13.3m13.1m34.9m12.5m19.4m13.2m15.2m

Inventories

11.7m9.8m10.7m14.1m14.7m16.8m18.4m20.5m15.1m12.9m14.1m11.7m12.5m10.1m10.4m11.3m10.3m10.8m13.0m11.0m13.7m10.7m11.9m13.3m11.8m13.2m13.7m14.3m12.6m12.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(134.0m)(171.9m)(162.0m)(53.9m)(81.2m)(153.5m)(96.7m)681.3m(440.7m)(444.4m)

Depreciation and Amortization

15.0m14.5m14.3m12.9m12.9m15.4m14.7m10.9m13.2m14.2m

Inventories

(5.4m)(5.6m)4.8m500.0k1.6m237.0k383.0k(655.0k)(1.3m)(2.6m)

Accounts Payable

(3.4m)(122.0k)6.2m(6.4m)(412.0k)518.0k2.1m971.0k13.0m2.4m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(36.0m)(72.4m)(96.5m)(41.1m)(75.4m)(118.9m)(55.1m)(97.8m)(114.4m)(46.2m)(78.8m)(8.2m)33.8m(18.8m)(27.0m)(19.5m)(68.1m)(111.3m)(63.9m)(123.7m)(62.9m)(95.8m)875.7m779.5m(118.5m)(228.4m)(327.2m)(138.7m)(218.7m)(327.2m)

Depreciation and Amortization

3.9m7.6m11.4m3.5m7.0m10.6m3.6m7.3m10.9m3.3m6.5m9.7m3.0m5.8m9.1m3.7m7.6m11.5m4.0m8.3m12.1m2.5m5.1m7.8m3.1m6.1m9.6m4.5m7.7m10.9m

Inventories

(4.4m)(2.5m)(3.4m)(1.5m)(2.1m)4.1m(112.0k)(2.2m)3.2m580.0k(659.0k)1.8m441.0k2.8m2.6m96.0k1.1m592.0k(1.9m)101.0k(2.5m)51.0k(1.2m)(2.6m)(397.0k)(1.8m)(2.3m)(1.7m)81.0k(227.0k)

Accounts Payable

(2.9m)(3.1m)(4.2m)(1.3m)80.0k(401.0k)1.4m2.6m697.0k(6.1m)(1.8m)(3.7m)2.2m(10.0k)(525.0k)(34.0k)17.0k4.8m4.1m3.2m5.7m6.5m5.8m2.6m5.2m3.5m16.1m2.7m425.0k(3.3m)
show all
USDQ1, 2011

Financial Leverage

2.5 x
Show all financial metrics

Nektar Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Nektar Therapeutics Online and Social Media Presence

Nektar Therapeutics's Trends

Embed Graph

Nektar Therapeutics Company Culture

  • Overall Culture

    B-

    74/100

  • CEO Rating

    C+

    70/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Nektar Therapeutics News and Updates

March 01, 2021

Nektar Therapeutics Stock Likely To See Higher Levels

Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company. Last week, Nektar announced that it has entered into a clinical trial collaboration and supply agreement with pharmaceutical giant...
February 18, 2021

Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, SNBR, GE, TWLO, and SAVE. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
February 01, 2021

Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, PFE, AZN, VIR, and ESPR. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
November 05, 2020

Nektar Therapeutics Reports Third Quarter 2020 Financial Results

SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketable securities at September 30, 2020 were approximately $1.2 billion as compared to $1.6 billion...
October 27, 2020

Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19

SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase...
January 25, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Show more

Nektar Therapeutics Blogs

May 18, 2021

Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)

-- Results demonstrate NKTR-255's differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent -- SAN FRANCISCO , May 18, 2021 /PRNewswire/ --  Nektar Therapeutics  (Nasdaq: NKTR) today announced the publication of preclinical
May 06, 2021

Nektar Therapeutics Reports First Quarter 2021 Financial Results

Nektar Therapeutics Reports First Quarter 2021 Financial Results Content Import Thu, 05/06/2021 - 16:21 Nektar Therapeutics Reports First Quarter 2021 Financial Results May 6, 2021 This release is a backfill from a News Wire Earnings …
April 27, 2021

Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , April 27, 2021 /PRNewswire/ --  Nektar Therapeutics  (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference
February 25, 2021

Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

SAN FRANCISCO , Feb. 25, 2021 /PRNewswire/ --  Nektar Therapeutics  (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.     Cash and investments in marketable securities at December 31, 2020 were approximately $1.2 billion as compared
February 18, 2021

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets Content Import Thu, 02/18/2021 - 17:30 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, Fe…
February 17, 2021

Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) Content Import Wed, 02/17/2021 - 08:04 Nektar Announces Agreement for Phase…
Show more

 Nektar Therapeutics Frequently Asked Questions

  • When was Nektar Therapeutics founded?

    Nektar Therapeutics was founded in 1990.

  • Who are Nektar Therapeutics key executives?

    Nektar Therapeutics's key executives are Jeff Ajer, Robert B. Chess and Gil M. Labrucherie.

  • How many employees does Nektar Therapeutics have?

    Nektar Therapeutics has 618 employees.

  • What is Nektar Therapeutics revenue?

    Latest Nektar Therapeutics annual revenue is $152.9 m.

  • What is Nektar Therapeutics revenue per employee?

    Latest Nektar Therapeutics revenue per employee is $247.4 k.

  • Who are Nektar Therapeutics competitors?

    Competitors of Nektar Therapeutics include Stingray Therapeutics, Kyowa Kirin and Cedilla Therapeutics.

  • Where is Nektar Therapeutics headquarters?

    Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco, San Francisco.

  • Where are Nektar Therapeutics offices?

    Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad.

  • How many offices does Nektar Therapeutics have?

    Nektar Therapeutics has 3 offices.